News & Updates
Filter by Specialty:
Serum S-adenosylhomocysteine linked to HCC survival
In patients with hepatocellular carcinoma (HCC), higher serum S-adenosylhomocysteine (SAH) concentrations may contribute to a shorter survival, regardless of the genetic variants of one-carbon metabolism key enzyme, according to a study.
Serum S-adenosylhomocysteine linked to HCC survival
26 Sep 2024
Ultra-low dose EBRT feasible in primary cutaneous B-cell lymphoma
Patients with primary cutaneous B-cell lymphoma (PCBCL) treated with ultra-low dose external beam radiation therapy (EBRT) to 4 Gy total dose in two fractions experience durable local control without skin toxicity, reports a study.
Ultra-low dose EBRT feasible in primary cutaneous B-cell lymphoma
23 Sep 2024
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
According to patient-reported outcomes (PROs) from the TROPiCS-02 study, sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) chemotherapy is associated with health-related quality of life (HRQoL) benefits across most symptoms and functioning domains among patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
